In this review, we discussed the key roles AP-1 proteins play in the pathobiology of cHL and ALK+ ALCL, the events that lead to the aberrant expression of these proteins, and how AP-1 transcriptional targets, or the components of pathways they function within, can be exploited as therapeutic targets. This evidence concerns the gene JUN and anaplastic large cell lymphoma.